PSA Testing Request

Clinical Scenario

David Thompson, 54, calls requesting a blood test. He is the sole carer for his son who has learning disabilities and wants to make sure he stays healthy. He has read about PSA testing online and wants to be screened for prostate cancer. He has hypertension controlled on amlodipine. He has no urinary symptoms, no family history of prostate cancer, and no other risk factors. He is anxious and determined to get tested.

What This Case Tests

Conducting an informed consent discussion for PSA testing; explaining the limitations of PSA as a screening tool (sensitivity, specificity, overdiagnosis); presenting the risk-benefit balance including the risks of investigation and treatment; shared decision-making when the patient has a strong agenda; acknowledging the patient's motivation (carer responsibility) while providing accurate information.

Common Mistakes Trainees Make

The three most common mistakes are: simply ordering the PSA without an informed consent discussion (PSA testing requires explicit informed consent per NHS guidelines), refusing the test without adequate explanation (dismissive and paternalistic), and failing to acknowledge the carer context — David's motivation to be screened comes from a genuine and admirable place, and this needs validating even while you explain the limitations of PSA.

The Consultation Challenge

David wants a PSA test because he is a devoted carer and cannot afford to become ill. His motivation is understandable and admirable. The consultation tests whether you can provide the informed consent discussion that PSA testing requires, without either rubber-stamping the request or dismissing it.

Start by understanding his motivation. Why does he want the test? What has he read? Does he have any urinary symptoms? Any family history of prostate cancer? This builds rapport and provides clinical context.

Explain what PSA can and cannot do. PSA is not a straightforward screening test like a blood pressure check. It has significant limitations: a normal PSA does not exclude prostate cancer (false negatives occur), and an elevated PSA often does not mean cancer (BPH, prostatitis, UTI, and even cycling can raise it). Approximately 75% of men with an elevated PSA who undergo biopsy do not have cancer.

Explain the consequences of an abnormal result. An elevated PSA leads to further investigation — typically MRI and potentially prostate biopsy. Biopsies carry risks (infection, bleeding, urinary retention). If cancer is found, it may be slow-growing cancer that would never have caused symptoms or shortened life — but once diagnosed, the psychological burden and treatment side effects (erectile dysfunction, urinary incontinence from surgery or radiotherapy) can significantly impact quality of life. This is the overdiagnosis problem.

Present the evidence. The UK National Screening Committee does not recommend routine PSA screening because the evidence shows that the harms (overdiagnosis and overtreatment) outweigh the benefits at a population level. However, any man over 50 who requests a PSA test after an informed discussion is entitled to one — this is the NHS PSA informed choice programme.

Make a shared decision. After the informed discussion, David may still want the test — and that is his right. The examiner is not testing whether you prevent the test, but whether you ensure the decision is genuinely informed. If David understands the limitations and still wants to proceed, arrange the test.

Time check: Spend the first 3 minutes understanding David's motivation and clinical context. By minute 7, complete the informed consent discussion covering limitations, false positives, investigation pathway, and overdiagnosis. Use minutes 8-10 for shared decision-making. Reserve the final 2 minutes for arranging the test (if requested) and follow-up.

How Examiners Mark This Case

Data Gathering and Diagnosis: Examiners assess whether you take a focused prostate history (urinary symptoms, family history, ethnicity — Black men have higher prostate cancer risk), understand why David wants the test (carer motivation), and screen for symptoms that would change the management (LUTS, haematuria, bone pain suggesting metastatic disease). If symptoms are present, this becomes a clinical assessment rather than a screening discussion.

Clinical Management and Medical Complexity: Examiners expect a comprehensive informed consent discussion covering: what PSA measures, its limitations (sensitivity, specificity), the investigation pathway if elevated (MRI, biopsy, risks), the overdiagnosis problem (finding cancers that would never cause harm), and the treatment side effects (erectile dysfunction, incontinence). They also look for knowledge of the NHS informed choice programme — any man over 50 who requests PSA after an informed discussion is entitled to it.

Relating to Others: Examiners assess whether you validate David's motivation (caring for his son), present the information in accessible language without medical jargon, and genuinely support his decision whichever way it goes. A trainee who lectures about overdiagnosis without acknowledging David's perspective will score poorly. The consultation should feel like a partnership, not a gate.

Example Opening

Strong opening: "Hello David, I can see you'd like a blood test. Before we go ahead, can you tell me what's prompted this? I want to make sure we do the right thing for you."

When explaining PSA limitations: "I completely understand why you want this — with everything you do for your son, you need to know you're healthy. The PSA test can be useful, but I want to make sure you know what it can and can't tell us before we go ahead. It's not quite as straightforward as some other blood tests."

When supporting his decision: "Now that you have the full picture, it's entirely your choice. If you'd still like the test, I'll arrange it. If you'd prefer to think about it, that's fine too. Either way, I'm here to support you."

Avoid: "PSA testing isn't recommended — there's no point doing it." (Dismissive and inaccurate — informed men over 50 are entitled to the test).

How This Appears in the SCA

PSA testing is a classic SCA shared decision-making case. The examiner is testing whether you can have the informed consent conversation — not whether you block or allow the test. This case combines clinical knowledge (PSA limitations), ethical reasoning (informed consent), and communication skills (explaining complex risk-benefit information in plain language).

Key Statistic

PSA has a sensitivity of approximately 70-80% for prostate cancer but a specificity of only 30-40%. Approximately 75% of men with an elevated PSA who undergo biopsy are found not to have cancer. The UK National Screening Committee does not recommend routine PSA screening due to the overdiagnosis and overtreatment risk.

Relevant Guidelines

• NHS PSA testing informed choice programme
• NICE NG12: Suspected cancer — recognition and referral
• NICE guideline on prostate cancer diagnosis and management.

Frequently Asked Questions

Do I need informed consent before ordering a PSA test in the SCA?

Yes — this is a core requirement. Unlike most blood tests, PSA testing requires explicit informed consent because of the significant implications of both positive and negative results. The NHS PSA informed choice programme mandates that men receive balanced information about the benefits and risks before testing. Ordering PSA without this discussion demonstrates poor clinical practice and will score poorly.

What are the key limitations of PSA I should explain?

PSA is not specific to prostate cancer — it is elevated in BPH, prostatitis, UTI, after ejaculation, and after cycling. Approximately 75% of men with elevated PSA who undergo biopsy do not have cancer. A normal PSA does not exclude cancer (15-20% of men with prostate cancer have a normal PSA). The overdiagnosis problem is significant: many cancers detected through screening are slow-growing and would never have caused symptoms or shortened life, but once diagnosed, carry psychological burden and treatment side effects.

Can I refuse to do a PSA test if the patient requests one?

No — under the NHS PSA informed choice programme, any man over 50 who requests a PSA test after receiving an informed consent discussion is entitled to have one. Your role is to ensure the decision is genuinely informed, not to prevent the test. If the patient understands the limitations and still wants to proceed, you should arrange it. Refusal after an informed request is not appropriate.

What if the patient has urinary symptoms — does this change the approach?

Yes — significantly. If the patient has lower urinary tract symptoms (LUTS), haematuria, or other concerning features, the consultation shifts from a screening discussion to a clinical assessment. PSA becomes part of the diagnostic workup rather than a screening test, and the informed consent framework changes accordingly. Always screen for symptoms before entering the screening discussion.

Are there men at higher risk who should be particularly informed about PSA testing?

Black men have approximately double the prostate cancer risk compared to white men, and men with a first-degree relative diagnosed with prostate cancer before 65 have increased risk. These men should be offered information about PSA testing proactively from age 45. Identifying these risk factors in the history demonstrates thorough Data Gathering and may change the framing of the informed consent discussion.